Lacerta Therapeutics is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. The company is based in Gainesville, FL and is a resident of UF Innovate | Sid Martin Biotech. Lacerta is led by President and CEO Joseph Reddy, Ph.D., and Chief Technology Officer Kenneth Warrington, Ph.D. The company closed a $30M funding round that will be used to advance its clinical pipeline. Sarepta Therapeutics made an equity investment and gained rights to multiple CNS-targeted gene therapy programs. Lacerta focuses on progressing its AAV-based programs through clinical development with the new capital.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2018